During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
|Videos|September 1, 2017
- Non-Small Cell Lung Cancer
- Volume 1
- Issue 1
Dr. Bazhenova on Considering Factors to Treat Non-Driver Patients With NSCLC With Bevacizumab
Author(s)Lyudmila A. Bazhenova, MD
Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses the factors to take into consideration when treating a patient with non-driver non–small cell lung cancer with bevacizumab (Avastin).
Advertisement
Articles in this issue
about 9 years ago
Current Treatment Strategies in Nonbiomarker Nonsquamous NSCLCabout 9 years ago
Emerging Treatment Strategies in Nonsquamous NSCLCabout 9 years ago
Nonbiomarker NSCLC Population a Challenging Obstacle, Expert Saysabout 9 years ago
Dr. Bazhenova on the Prevalence of Patients With Non-Driver NSCLCAdvertisement
Related to this article
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
FDA grants 2 breakthrough therapy designations to Temab-A, speeding development for hard-to-treat colorectal cancer and c-Met–expressing lung cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
2
Durability of PFS and OS Benefit vs. Historical Control
3
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
4
VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors
5